Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Personalis Inc. (PSNL:NASDAQ), powered by AI.
Personalis Inc. is currently trading at $9.69. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Personalis Inc. on Alpha Lenz.
View Personalis Inc.'s valuation metrics on Alpha Lenz.
“Personalis Inc.'s ROE is -35.0%. Explore profitability and growth together.”
Ask for details →Personalis Inc. is a biotechnology company specializing in advanced genomics services for precision medicine and oncology. Its primary function is to analyze complex genetic information for clinical and academic research, aiding in the development of targeted therapeutics and personalized treatments. The company's offerings include a comprehensive platform that integrates genomic data generation with advanced bioinformatics, focusing particularly on cancer genomics and the immune response. Personalis Inc. collaborates with leading research institutions, biopharmaceutical companies, and healthcare providers to enhance the understanding of disease mechanisms and improve therapeutic strategies. Headquartered in Menlo Park, California, Personalis plays a significant role in the biotech industry by contributing to innovations in personalized healthcare, precision diagnostics, and genomics-driven therapeutic development.
“Personalis Inc.'s ROE is -35.0%. Explore profitability and growth together.”
Ask for details →Personalis Inc. (ticker: PSNL) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 228 employees.
The current price is $9.69 with a P/E ratio of -x and P/B of -x.
ROE is -35.02% and operating margin is -126.43%. Annual revenue is $70M.